Solid Biosciences Inc. — Director's Dealing 2026

Feb 2, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Solid Biosciences Inc. (SLDB)
CIK: 0001707502
Period of Report: 2026-01-29

Reporting Person: Herzich Paul (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-01-29	Common Stock	M	54925	—	Acquired	81547	Direct
2026-01-31	Common Stock	M	24675	—	Acquired	106222	Direct
2026-02-02	Common Stock	S	26250	$6.4369	Disposed	79972	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-01-29	Performance Stock Units	$	M	54925	Disposed		Common Stock (54925)	Direct
2026-01-29	Employee Stock Option (Right to Buy)	$6.60	A	170000	Acquired	2036-01-29	Common Stock (170000)	Direct
2026-01-29	Restricted Stock Units	$	A	85000	Acquired		Common Stock (85000)	Direct
2026-01-31	Restricted Stock Units	$	M	24675	Disposed		Common Stock (24675)	Direct

Footnotes

F1: Each performance stock unit ("PSUs") converts to common stock on a one-for-one basis.

F2: Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis.

F3: This sale was made to cover withholding taxes following the vesting of previously granted PSUs pursuant to a durable automatic sale instruction letter adopted by Mr. Herzich on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Herzich.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.295 to $6.580, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.

F5: The PSUs were granted on June 11, 2024 and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"), subject to the grantee's continued service with the Company (the "Approval Conditions"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the first Performance Milestone was determined to be met on January 29, 2026 (the "2026 Grant Date") resulting in the vesting of the PSUs as to 25% of the underlying shares.

F6: This option was granted on the 2026 Grant Date and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the 2026 Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary.

F7: The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary.

F8: On January 31, 2025 (the "2025 Grant Date"), the reporting person was granted 98,700 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary.